Who Is Mounjaro For, and Does It Apply to You?

You've heard it mentioned, but who is it actually designed for?

Most people arrive at this question because someone mentioned Mounjaro at work, or they spotted it in a news headline, or their GP said something vague about new weight-loss options. The natural follow-up is: does any of this apply to me?

Mounjaro is tirzepatide, a molecule that binds two gut-hormone receptors simultaneously, delivered as a once-weekly injection made by Eli Lilly. It targets two gut-hormone receptors (GIP and GLP-1) that work together to reduce appetite, slow how quickly food leaves the stomach, and help regulate blood sugar. No other weight-loss medicine licensed in the UK does both at once. That dual action is why the trial results drew attention: in the SURMOUNT-1 study, participants at the highest dose lost around 20–21% of their body weight on average over 72 weeks, which sits above what single-pathway medicines had achieved in comparable settings.

Who it is designed for, formally, is adults with a BMI of 30 or above, or adults with a BMI of at least 27 who have one or more weight-related conditions, prediabetes, hypertension, obstructive sleep apnoea and dyslipidaemia are all recognised examples. For certain ethnic backgrounds, including South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the qualifying BMI is 2.5 kg/m² lower under UK clinical guidance. Mounjaro also holds a separate licence for type 2 diabetes, so some people will be prescribed it for that reason rather than weight alone.

One misconception worth letting go: Mounjaro is not a quick fix for people who want to lose a few kilograms before a holiday. The MHRA is explicit that GLP-1 and dual-agonist medicines are not assessed or licensed for cosmetic weight loss.

The prescriber's assessment, what they are weighing up beyond your BMI

A BMI number opens the door; it does not walk you through it. When a prescriber at an online pharmacy like nume (sorry, a service such as ours) reviews a consultation, they are reading the whole clinical picture.

That includes your current medications, because some combinations need careful thought. Women taking oral contraceptives, for example, are advised to add a barrier method for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, since the medicine slows gastric emptying and may reduce how reliably the pill is absorbed. Transdermal HRT (patches or gels) is the preferred form for women on HRT during treatment, for the same reason. These are not reasons to avoid Mounjaro; they are reasons why a proper clinical assessment matters before you start.

Your prescriber will also consider whether certain conditions make Mounjaro unsuitable. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), a history of pancreatitis, or certain gastrointestinal conditions will each prompt a careful conversation. Pregnancy, breastfeeding and active attempts to conceive are clear contraindications, the medicine is not recommended in any of those situations, and under-18s fall outside the licence entirely.

At our clinical team, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the same day it is submitted. No automated system makes the call.

NHS eligibility versus private treatment, the practical difference

There is sometimes confusion about whether Mounjaro is "available on the NHS". The short answer is: yes, but under criteria that most people cannot yet meet, and with phased rollout that varies by area.

NICE recommended tirzepatide for NHS use in December 2024 (guidance TA1026), but the conditions are specific: a BMI of 35 or above plus at least one qualifying comorbidity, within a managed care setting. The rollout is phased, earlier cohorts needed four or more of the five recognised conditions alongside a BMI of 40 or above. GP practices have been able to prescribe it under a new contract arrangement from April 2026, but participation is optional and availability differs between practices and regions.

For people who do not meet the NHS criteria, or who prefer not to wait, a private prescription route through a regulated pharmacy is the legal alternative. If you are curious about which pharmacies and providers are legally authorised to supply Mounjaro privately, our dedicated page covers that in detail, alongside what the consultation process involves. NICE's published appraisal sets out the NHS criteria in detail if you want to compare your situation against them directly.

One practical note on cost: private Mounjaro pricing has shifted significantly since the company that owns the Mounjaro brand raised UK list prices in September 2025. Typical private monthly costs now range roughly £149–£375 depending on dose and provider, context that matters when you are weighing up whether private treatment is viable. Our weight-loss overview explains what a transparent private price should include.

What starting treatment actually looks like

If a prescriber decides Mounjaro is clinically appropriate, treatment begins at 2.5 mg. That starting dose exists to give your digestive system time to adjust, nausea and other gastrointestinal effects are most common in the early weeks, and a lower opening dose reduces their intensity. The 2.5 mg pen is not where the clinical effect sits; that comes progressively as the dose is titrated, typically in four-week steps, up to a maximum of 15 mg.

Each pen delivers four weekly doses via a subcutaneous injection into the abdomen, thigh or upper arm. Rotating the injection site each week reduces local reactions. The pen is stored in the fridge (between 2 and 8°C) and the Patient Information Leaflet details the maximum time it can safely spend at room temperature before use; that figure is worth reading carefully rather than guessing.

Full details of the dosing schedule, storage windows and what to do if a dose is missed sit in the Mounjaro Patient Information Leaflet, available via the electronic Medicines Compendium. What a prescriber decides about your specific titration is a clinical conversation, not something a webpage should shortcut.

If you think Mounjaro might be relevant for you, the place to start is a consultation. If you would like background on the research and development history behind Mounjaro, that page sets out how the medicine came to exist before you decide whether to proceed. Our prescribers can assess whether it is suitable for your situation, and if you want to understand who makes Mounjaro and what that means for how it is produced and supplied, that page covers the full picture. Speak to our prescribers through the free consultation, it takes a few minutes, and you get a same-day clinical response.